{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:16:20Z","timestamp":1789031780450,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40262-025-01539-8","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T01:32:07Z","timestamp":1750987927000},"page":"1245-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SHR-1918, A Monoclonal Antibody Against Angiopoietin-Like 3, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct05432544","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ruzhai","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lika","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"15","key":"1539_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/heartjnl-2023-322928","volume":"110","author":"A Rout","year":"2024","unstructured":"Rout A, Duhan S, Umer M, Li M, Kalra D. Atherosclerotic cardiovascular disease risk prediction: current state-of-the-art. Heart. 2024;110(15):1005\u201314. https:\/\/doi.org\/10.1136\/heartjnl-2023-322928.","journal-title":"Heart"},{"issue":"11","key":"1539_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","volume":"45","author":"L Nedkoff","year":"2023","unstructured":"Nedkoff L, Briffa T, Zemedikun D, Herrington S, Wright FL. Global trends in atherosclerotic cardiovascular disease. Clin Ther. 2023;45(11):1087\u201391. https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.020.","journal-title":"Clin Ther"},{"issue":"8","key":"1539_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","volume":"134","author":"J Underberg","year":"2022","unstructured":"Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134(8):752\u201362. https:\/\/doi.org\/10.1080\/00325481.2022.2117498.","journal-title":"Postgrad Med"},{"issue":"9","key":"1539_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","volume":"78","author":"SS Virani","year":"2021","unstructured":"Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021;78(9):960\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.011.","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"1539_CR5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/s0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(10)61350-5.","journal-title":"Lancet"},{"issue":"9943","key":"1539_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626\u201335. https:\/\/doi.org\/10.1016\/s0140-6736(14)61177-6.","journal-title":"Lancet"},{"issue":"3","key":"1539_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/CIRCRESAHA.118.313171","volume":"124","author":"RA Hegele","year":"2019","unstructured":"Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019;124(3):386\u2013404. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313171.","journal-title":"Circ Res"},{"issue":"2","key":"1539_CR8","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81. https:\/\/doi.org\/10.1161\/ATV.0000000000000073.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1539_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11936-017-0556-0","volume":"19","author":"A Durairaj","year":"2017","unstructured":"Durairaj A, Sabates A, Nieves J, Moraes B, Baum S. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and its inhibitors: a review of physiology, biology, and clinical data. Curr Treat Options Cardiovasc Med. 2017;19(8):58. https:\/\/doi.org\/10.1007\/s11936-017-0556-0.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"19","key":"1539_CR10","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088\u201393. https:\/\/doi.org\/10.1161\/01.CIR.98.19.2088.","journal-title":"Circulation"},{"issue":"1","key":"1539_CR11","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2017.6","volume":"2017","author":"M Hassan","year":"2017","unstructured":"Hassan M. ANGPLT3: a novel modulator of lipid metabolism. Glob Cardiol Sci Pract. 2017;2017(1): e201706. https:\/\/doi.org\/10.21542\/gcsp.2017.6.","journal-title":"Glob Cardiol Sci Pract."},{"issue":"12","key":"1539_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13(12):731\u20139. https:\/\/doi.org\/10.1038\/nrendo.2017.119.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"1539_CR13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1161\/circresaha.120.317128","volume":"127","author":"L Wu","year":"2020","unstructured":"Wu L, Soundarapandian MM, Castoreno AB, Millar JS, Rader DJ. LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase. Circ Res. 2020;127(8):1112\u20134. https:\/\/doi.org\/10.1161\/circresaha.120.317128.","journal-title":"Circ Res"},{"issue":"2","key":"1539_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","volume":"52","author":"A Tikka","year":"2016","unstructured":"Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016;52(2):187\u201393. https:\/\/doi.org\/10.1007\/s12020-015-0838-9.","journal-title":"Endocrine"},{"key":"1539_CR15","unstructured":"US Food and Drug Administration. FDA approves add-on therapy for patients with genetic form of severely high cholesterol. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0. Accessed 28 Apr 2024."},{"key":"1539_CR16","unstructured":"World Heart Federation. World Heart Report 2023: Confronting the World\u2019s Number One Killer. Geneva, Switzerland. 2023. https:\/\/world-heart-federation.org\/wp-content\/uploads\/World-Heart-Report-2023.pdf. Accessed 28 Apr 2024."},{"issue":"1","key":"1539_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/jcm12010168","volume":"12","author":"B Sosnowska","year":"2022","unstructured":"Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia. J Clin Med. 2022;12(1):168. https:\/\/doi.org\/10.3390\/jcm12010168.","journal-title":"J Clin Med"},{"issue":"24","key":"1539_CR18","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2031049.","journal-title":"N Engl J Med"},{"issue":"6","key":"1539_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/circulationaha.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470\u201386. https:\/\/doi.org\/10.1161\/circulationaha.118.039107.","journal-title":"Circulation"},{"issue":"3","key":"1539_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"issue":"8","key":"1539_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"issue":"7","key":"1539_CR22","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","volume":"11","author":"BC Mackness","year":"2019","unstructured":"Mackness BC, Jaworski JA, Boudanova E, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. MAbs. 2019;11(7):1276\u201388. https:\/\/doi.org\/10.1080\/19420862.2019.1633883.","journal-title":"MAbs"},{"key":"1539_CR23","unstructured":"US Food and Drug Administration. EVKEEZA (evinacumab-dgnb) injection, for intravenous use. 2021. FDA approved drug products. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761181s000lbl.pdf. Accessed 17 June 2025."},{"key":"1539_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.10.013","volume":"314","author":"M Harada-Shiba","year":"2020","unstructured":"Harada-Shiba M, Ali S, Gipe DA, et al. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis. 2020;314:33\u201340. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.10.013.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1539_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/01.Atv.0000252827.51626.89","volume":"27","author":"M Shimamura","year":"2007","unstructured":"Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007;27(2):366\u201372. https:\/\/doi.org\/10.1161\/01.Atv.0000252827.51626.89.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1539_CR26","doi-asserted-by":"publisher","unstructured":"Dewey Frederick E, Gusarova V, Dunbar Richard L, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 377(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1612790.","DOI":"10.1056\/NEJMoa1612790"},{"key":"1539_CR27","doi-asserted-by":"publisher","unstructured":"Engler C, Ebenbichler C. Evinacumab to treat hypercholesterolemia. Drugs Today (Barc). 57(10):607\u201319. https:\/\/doi.org\/10.1358\/dot.2021.57.10.3317240.","DOI":"10.1358\/dot.2021.57.10.3317240"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01539-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:42:15Z","timestamp":1752594135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01539-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01539-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Chao Lv, Min Zhu, and Shihui Wang are employees of Hengrui. Ruzhai Qin, Lika Ye, Lian Duan, Mingyan Li, Wenkai He, Xiao Mei, Deen Li, Rong Jin, and Zhihong Xie have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol and all amendments were approved by the Clinical Trial Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University. The study was conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}